Leczenie testosteronem – wskazania, skuteczność i ryzyko zdrowotne

Testosterone, the principal androgenic steroid hormone, constitutes one of the most biologically significant hormonal compounds in male physiology. Its biosynthesis occurs predominantly within the interstitial Leydig cells situated in the testicular tissue, with supplementary production taking place in the adrenal cortex, ovarian tissues in females, and the placental unit during gestation. The secretion of testosterone is meticulously governed by luteinizing hormone (LH), which is released by the anterior pituitary gland. The primary physiological roles of testosterone encompass the orchestration and activation of male pubertal development, including the manifestation of secondary sexual characteristics such as facial hair growth, pubic hair distribution, vocal cord thickening (resulting in voice deepening), spermatogenic maturation, and the formation of the laryngeal prominence (commonly referred to as the "Adam’s apple"). Beyond these functions, testosterone exerts a profound influence on the structural and functional integrity of the male reproductive system, directly impacting spermatogenesis, the development of seminiferous tubules, and the epididymal ducts. Its significance extends to sexual drive (libido) and overall sexual performance. Furthermore, testosterone demonstrates potent anabolic properties by stimulating muscular protein synthesis, thereby facilitating muscle mass accretion and ensuring appropriate muscular tissue distribution across the body in both sexes. However, its physiological relevance transcends gender-specific domains: this hormone modulates mood regulation, bone tissue metabolism, and in females, it additionally governs ovarian function while influencing sexual desire.

The primary driver behind the decline in testosterone concentrations in males is the inevitable, age-associated physiological involution of bodily systems. Commencing around the fourth decade of life, there is a measurable, progressive diminution in the endogenous biosynthesis of this critical androgen. It is essential to emphasize, however, that the trajectory of this decline exhibits substantial interindividual variability and is intimately linked to lifestyle factors. Accelerated reduction may be attributable to chronic excessive alcohol consumption, long-standing nicotine dependence, prolonged exposure to psychosocial stressors, the use of psychotropic or illicit substances, as well as both insufficient and excessive levels of physical exertion. Furthermore, hypogonadism may emerge as a secondary manifestation of numerous pathological conditions, including but not limited to acute or chronic testicular inflammation, chromosomal abnormalities such as Klinefelter syndrome, hypothalamic dysfunction, pituitary adenomas, or hypogonadotropic hypogonadism. Diminished androgen levels precipitate a cascade of deleterious health outcomes, particularly within the reproductive and sexual domains. Affected individuals frequently report deteriorated semen parameters, erectile dysfunction, and reduced sexual desire. Common comorbid symptoms encompass generalized lethargy, persistent fatigue, sleep architecture disturbances, diminished self-esteem, heightened irritability, and emotional lability. Morphological alterations extend to skeletal muscle—specifically, reduced lean body mass—as well as secondary sexual characteristics, including testicular atrophy, hair thinning or alopecia, and the development of glandular breast tissue (gynecomastia). Notably, hypogonadism frequently co-occurs with systemic disorders such as type 2 diabetes mellitus, chronic obstructive pulmonary disease (COPD), reduced bone mineral density (osteoporosis), and metabolic syndrome. Age-related hormonal dysregulation also predisposes to benign prostatic hyperplasia, which may subsequently lead to lower urinary tract symptoms (e.g., urinary incontinence, frequency), impaired fertility, perineal and lumbar spinal pain, and low-grade fever. In some cases, untreated prostatic enlargement may progress to prostate carcinoma. In females, androgen deficiency primarily manifests as decreased libido and ovulatory dysfunction.

Testosterone replacement therapy (TRT) represents a targeted hormonal intervention designed to restore serum testosterone concentrations to physiologically appropriate levels corresponding to the patient’s age-specific reference ranges. The therapeutic target typically falls within 450–600 nanograms per deciliter (ng/dL). Beyond normalization of androgen levels, TRT is intended to mitigate or resolve symptomatic manifestations of endogenous testosterone deficiency. The primary clinical indication for initiating TRT is the diagnosis of hypogonadism—whether primary (testicular failure) or secondary (hypothalamic-pituitary axis dysfunction). However, the scope of indications extends to additional conditions, including diminished libido, andropausal symptoms (male climacteric), erectile dysfunction, chronic fatigue, psychological distress (such as reduced self-esteem), and overall decline in quality of life. Furthermore, TRT may serve as an adjunctive treatment in metabolic disorders—such as insulin resistance or dyslipidemia—as well as in hormonal imbalances precipitated by high-intensity resistance training. Patient eligibility for TRT is contingent upon comprehensive laboratory assessment, with total testosterone (TT) measurements performed twice during morning hours (between 8:00 AM and 11:00 AM), when concentrations peak. Diagnostic thresholds are informed by guidelines from professional medical societies, though individual adjustments may apply: For instance, the *Endocrine Society* (2018) and *American Urological Association* (2018) define deficiency as TT < 300 ng/dL, whereas the *International Society for Sexual Medicine* (2015) adopts a threshold of TT < 350 ng/dL. Available testosterone formulations vary not only in administration routes (oral, intranasal, transdermal, subcutaneous, intramuscular) but also in composition, dosing regimens, pharmacokinetic profiles, and safety considerations.

Prior to initiating testosterone replacement therapy (TRT), a comprehensive series of diagnostic evaluations must be conducted to ensure both the safety and efficacy of the proposed treatment regimen. A fundamental component of this preparatory phase involves the meticulous assessment of hematological indices, with particular emphasis on hemoglobin and hematocrit levels. Should the hematocrit value exceed 50%, the commencement of hormonal therapy must be postponed indefinitely, as elevated blood parameters pose a significant health hazard—most notably, an increased susceptibility to thromboembolic events. Continuous hematological monitoring throughout the duration of TRT is mandatory; in instances where alarmingly high hematocrit or hemoglobin levels are detected, temporary or permanent discontinuation of treatment may become necessary. An equally critical consideration is the measurement of prostate-specific antigen (PSA) concentrations, which serves as the primary diagnostic biomarker for prostate cancer. While TRT itself does not directly induce neoplastic development, thorough pre-treatment screening in men aged 40 and above is essential to rule out the presence of occult malignancies. In cases where diminished testosterone levels are attributable to active prostate cancer, oncological intervention takes precedence over hormonal therapy. Existing scientific evidence (e.g., Gruenewald & Matsumoto, 2003) suggests that the administration of exogenous testosterone may potentially accelerate the progression of pre-existing tumorous lesions, a phenomenon correlated with elevated PSA levels. Potential risks associated with TRT include: erythrocytosis, an heightened predisposition to venous thrombosis and embolism, increased blood viscosity (hyperviscosity), possible hepatotoxicity, exacerbation of benign prostatic hyperplasia symptoms, and impairments in spermatogenesis—ranging from azoospermia and oligospermia to outright infertility in severe cases.

A fundamental component of monitoring testosterone replacement therapy (TRT) involves conducting periodic laboratory assessments to determine serum testosterone concentrations. According to current clinical guidelines, the initial evaluation should occur at the three-month mark following therapy initiation, with a subsequent assessment at six months. For long-term monitoring, annual testosterone level measurements are recommended. The efficacy of treatment must be evaluated not solely through laboratory findings but also by assessing the degree of symptom alleviation associated with androgen deficiency, including manifestations of hypogonadism or andropause. Should clinical symptoms fail to improve despite achieving target testosterone levels, the continuation of TRT lacks medical justification and should be discontinued. It is essential to note that improvements in specific health parameters occur within well-defined timeframes: increases in lean muscle mass, enhancements in libido, and sexual function typically manifest between the third and sixth month of therapy, whereas significant improvements in bone mineral density generally require approximately two years of consistent treatment.